Title:Effect of Intranasal Administration of Galanin-like Peptide (GALP) on Body Weight and Hepatic Lipids Accumulation in Mice with Diet-induced Obesity
VOLUME: 23 ISSUE: 25
Author(s):Satoshi Hirako, Nobuhiro Wada, Haruaki Kageyama, Fumiko Takenoya, Hyounju Kim, Yuzuru Iizuka, Akiyo Matsumoto, Mai Okabe and Seiji Shioda*
Affiliation:Department of Health and Nutrition, University of Human Arts and Sciences, Saitama, Department of Internal Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Faculty of Health Care, Kiryu University, Gunma, Department of Exercise and Sports Physiology, Hoshi University School of Pharmacy and Pharmaceutical Science, Department of Clinical Dietetics & Human Nutrition, Faculty of Pharmaceutical Sciences, Josai University, Saitama, Department of Clinical Dietetics & Human Nutrition, Faculty of Pharmaceutical Sciences, Josai University, Saitama, Department of Clinical Dietetics & Human Nutrition, Faculty of Pharmaceutical Sciences, Josai University, Saitama, Tokyo Shokuryo Dietitian Academy, Tokyo, Hoshi University School of Pharmacy and Pharmaceutical Sciences Global Research Center for Innovative Life Science, Peptide Drug Innovation, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501
Keywords:GALP, fatty liver, lipid metabolism, high fat diet, DIO, triglycerides.
Abstract:Galanin-like peptide (GALP) is a neuropeptide involved in the regulation of food intake behavior,
body weight and energy metabolism. In previous studies, we demonstrated that the intranasal administration of
GALP has weight loss effects, although the mechanism of this action was not clarified. The aim of this study was
to demonstrate the functional significance of GALP on lipid metabolism in the liver. Mice were fed a high fat diet
to cause diet-induced obesity (DIO) and then administered GALP intranasally for 2 weeks (experimental), or
vehicle (control). Body weights, along with lipid levels in the plasma and liver, and lipid metabolism-related gene
expression in the liver were subsequently measured. Body weight gain was decreased by the GALP treatment
compared to the control group. Lipid droplet levels in hepatocytes and hepatic triglyceride levels were decreased
in the GALP group compared with the vehicle group, whereas hepatic fatty acid β-oxidation-related gene mRNA
levels were increased in the GALP group. These results suggest that the intranasal administration of GALP has an
inhibitory effect on lipid accumulation in the liver.
